Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

Figure 1

Study design. Sequential dose-escalation, randomized, double-blind, placebo controlled study design with an extension at the highest dose level. ACZ885 was administered intravenously on days 1 and 15 (arrows). Safety data generated up to day 20 in each cohort were reviewed before escalating to the next higher dose level. Independent observer efficacy assessments were made at day 1, before dosing, and day 43, in addition to weekly investigator assessments up to Day 43. The end of study was on day 113. After safety review of the first six patients at 10 mg/kg, an extension cohort was started, which included 14 patients on ACZ885 and seven patients on placebo (pbo).

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us